BioMarin Pharmaceutical Inc. - Common Stock (BMRN)

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) met Wall Street’s revenue expectations in Q3 2026, with sales up 32% year on year to $1.02 billion. On ...

Revenue topped $1 billion for first time, fueled by Amicus integration.

BioMarin Pharmaceutical (NASDAQ:BMRN) reported third-quarter revenue above $1 billion for the first time, driven by growth across its rare-disease portfolio and contributions from acquired Amicus Therapeutics products. The company said revenue increased 32% year over year, while its metabolic condit

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) met Wall Street’s revenue expectations in Q3 2026, with revenue up 32% year on year to $1.02 billion. O...

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be announcing earnings results tomorrow after market hours. Here’s what investors should know. Bio...

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have...

BioMarin Pharmaceutical (NASDAQ:BMRN) said it is progressing with the integration of Amicus Therapeutics while pursuing additional business-development opportunities, as executives outlined growth plans for newly acquired rare-disease products, VOXZOGO and several pipeline programs at Morgan Stanley

Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to beco...

BioMarin Pharmaceutical trades at $66.53 and has moved in lockstep with the market. Its shares have returned 9.3% over the last six months while the S&P 500 ...

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking a...

What Happened? Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 3.3% in the afternoon session after the company agreed to acquire Alest...

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not...

BioMarin Pharmaceutical (NASDAQ:BMRN) outlined its growth strategy, integration plans for Amicus Therapeutics and pipeline priorities during a Canaccord discussion with Chief Financial Officer Brian Mueller. Mueller described BioMarin as one of the largest rare-disease-focused biopharmaceutical com

What Happened? Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 2.6% in the morning session after an analyst at Canaccord Genuity raise...

BioMarin Pharmaceutical (NASDAQ:BMRN) reported second-quarter 2026 revenue of nearly $1 billion, up 20% from a year earlier, as growth across its rare-disease portfolio and the recently completed Amicus acquisition supported results. The company raised its full-year revenue, VOXZOGO revenue and non-

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 19.9% year on year ...

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting results this Thursday after the bell. Here’s what investors should know. BioMarin Pha...

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...